Navigation Links
For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders' Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
Date:4/4/2013

BURLINGTON, Mass., April 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that most influences their decisions regarding prescribing in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Amgen/UCB's AMG-785/CDP-7851 and Merck's odanacatib have advantages over patient share leader alendronate (Merck's Fosamax, Teijin's Bonalon, generics) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Emerging Therapies AMG-785/CDP-781 and Odanacatib Are Poised to Overtake Teriparatide's Status as the Clinical Gold Standard also finds that, based on clinical data and the opinions of interviewed thought leaders, teriparatide (Eli Lilly's Forteo/Forsteo, Asahi Kasei's Teribone) is Decision Resources' current proprietary clinical gold-standard therapy for osteoporosis and osteopenia. Teriparatide has the strongest clinical profile among key marketed products that treat osteoporosis and osteopenia. However, AMG-785/CDP-7851 is expected to displace teriparatide and will earn proprietary clinical gold-standard status for osteoporosis and osteopenia in 2021, following its launch for the indication in 2017. AMG-785/CDP-7851 has competitive advantages in safety and tolerability as well as delivery over teriparatide and advantages in efficacy and safety over the current standard of care, alendronate.

"It is important to note, however, that AMG-785/CDP-7851 is considered only marginally better than odanacatib, which falls just short of being the future clinical gold standard," said Decision Resources Analyst Pam Narang , Ph.D. "Furthermore, although thought leaders expect AMG-785/CDP-7851 to offer superiority over alendronate across all efficacy attributes, the drug's anticipated safety and tolerability profile gives it the edge over current and emerging osteoporosis and osteopenia agents."

According to insights from surveyed U.S. and European PCPs and managed care organization (MCO) pharmacy directors, greater reduction in the risk of vertebral fracture is one of the greatest unmet needs in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Radius Health's BA-058 and AMG-785/CDP-7851 have demonstrated the potential to significantly fulfill this unmet need.

The report also finds that surveyed U.S. MCO pharmacy directors are particularly receptive to new osteoporosis and osteopenia therapies that offer 50 percent better reduction in the risk of vertebral fractures over currently available therapies. Decision Resources expects that BA-058 and AMG-785/CDP-7851 will match the improvements on vertebral fracture risk reduction that surveyed U.S. payers indicated would be required for widespread inclusion on MCO formularies.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
2. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
3. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
8. AG Mednet and Japans Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market
9. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
10. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology ... Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at ... Society of Clinical Oncology (ASCO), taking place January 19-21, ... "AM0010 induces the expansion of novel ... cells in the blood and tumors of our patients," ...
(Date:1/20/2017)... Jan 20, 2017 Research and Markets ... Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales ... their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and ... high-growth hearing aid industry. The growing prevalence of ...
(Date:1/20/2017)... PARK, Fla. , Jan. 20, 2017 Wells ... located at 3796 Howell Branch Rd in Winter ... Winter Park . Operations have been consolidated ... Specialty Pharmacy is also pleased to announce that Chad ... to President of the Company effective immediately. Mr. Tomlinson is ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... the largest manufacturer of oats in China, is now aiming at global business expansion, ... globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly recommends ... sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are the ...
(Date:1/21/2017)... ... 21, 2017 , ... Pacifica Graduate Institute’s Alumni Association announced ... events for its annual meeting “Coming Home 2017,” an activity-packed weekend of educational ... will be held on Friday January 27 through Sunday, January 29, 2017 at ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... 2017 , ... A new partnership between Goodwill® and Roadie, Inc. aims to ... from clothes to couches to dressers and bicycles. Roadie — the national on-the-way delivery ... Goodwill donation center through February 28th. , “January is an exciting time when ...
Breaking Medicine News(10 mins):